Breaking News Instant updates and real-time market news.

EIDX

Eidos Therapeutics

$19.68

0.77 (4.07%)

09:34
03/18/19
03/18
09:34
03/18/19
09:34

Eidos Therapeutics reports publication of AG10 trial in JACC

Eidos Therapeutics announced the publication of its Phase 2 clinical trial studying AG10 in subjects with symptomatic TTR amyloid cardiomyopathy in the Journal of the American College of Cardiology entitled "Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy". Eidos also presented subgroup analyses from the same Phase 2 clinical study in an oral presentation at this year's American College of Cardiology Scientific Sessions. Stephen Heitner, M.D., director of the hypertrophic cardiomyopathy clinic at the Oregon Health & Science University, presented these findings in an oral presentation entitled "AG10 Consistently Stabilizes Transthyretin to a High Level in Both Wild Type and Mutant Amyloid Cardiomyopathy: Responder Analyses From a Phase 2 Clinical Trial". "These data confirm the potential ability of AG10 to treat ATTR-CM, regardless of mutational status," said Jonathan Fox, MD, PhD, president and chief medical officer of Eidos. "The observed near-complete stabilization of TTR in all actively treated subjects and across the dosing interval provide clinical proof-of-concept for AG10 in both wild-type and mutant ATTR-CM. These Phase 2 results support further investigation of AG10 in the ongoing ATTRibute-CM Phase 3 study." The primary results from the Phase 2 study were presented at the 2018 American Heart Association Annual Meeting in Chicago, IL on November 10, 2018.

  • 18

    Mar

  • 25

    Mar

  • 26

    Mar

EIDX Eidos Therapeutics
$19.68

0.77 (4.07%)

02/21/19
BMOC
02/21/19
INITIATION
BMOC
Outperform
Eidos Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst George Farmer initiated Eidos Therapeutics with an Outperform rating and $28 price target. The analyst receommends buying shares as he sees huge potential for AG10 for the treatment of transthyretin amyloidosis, and estimates peak sales of $3B by 2031.
02/27/19
JPMS
02/27/19
UPGRADE
JPMS
Overweight
Eidos Therapeutics upgraded to Overweight from Neutral at JPMorgan
02/27/19
JPMS
02/27/19
UPGRADE
Target $39
JPMS
Overweight
JPMorgan says Eidos trial design removes multiple overhangs, ups to Overweight
JPMorgan analyst Anupam Rama upgraded Eidos Therapeutics to Overweight from Neutral, citing his view that the company's design of the ATTRibute-CM study, which incorporates feedback from the FDA, removes multiple overhangs, including the need for a head-to-head study versus tafamidis and a financing overhang. The analyst, who has increased his view of the probability of success for AG10 in the ATTR-CM opportunity, also believes AG10 is likely to generate strategic interest from commercial partners. Rama raised his price target on Eidos shares to $39 from $29.
02/27/19
ROTH
02/27/19
NO CHANGE
Target $28
ROTH
Buy
Eidos addressed stock major overhangs with smart trial design, says Roth Capital
Roth Capital analyst Yasmeen Rahimi believes that Eidos Therapeutics' ATTRibute-CM "smart trial design offers the best of both worlds" with two approvable endpoints, namely a 12-month, placebocontrolled study with primary endpoint of change from baseline in six-minute walk distance, and reduction in all-cause mortality and frequency of CV-related hospitalizations over 30 months. Overall, the analyst thinks the company has addressed the major stock overhangs with this smart design. First, by not waiting for tafamidis approval for a comparator, Eidos Therapeutics' will start its trial six months faster and shorten time to market, and second, it is now "rich in catalysts," Rahimi contends. The analyst reiterates a Buy rating and $28 price target on the shares.

TODAY'S FREE FLY STORIES

FITB

Fifth Third

$27.59

0.64 (2.37%)

15:12
06/18/19
06/18
15:12
06/18/19
15:12
Hot Stocks
Fifth Third jumps almost 2.5% after raising dividend, new 100M buyback »

Shares of Fifth Third…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

JBL

Jabil

$27.45

0.655 (2.44%)

15:04
06/18/19
06/18
15:04
06/18/19
15:04
Options
Jabil Circuit options imply 11.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

14:55
06/18/19
06/18
14:55
06/18/19
14:55
General news
FOMC forecast preview: »

FOMC forecast preview:…

APC

Anadarko

$70.00

0.21 (0.30%)

14:52
06/18/19
06/18
14:52
06/18/19
14:52
Periodicals
Anadarko gives go-ahead on $20B LNG export project in Mozambique, Reuters says »

Anadarko Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSP

E.W. Scripps

$15.02

0.01 (0.07%)

, CBS

CBS

$49.38

0.22 (0.45%)

14:50
06/18/19
06/18
14:50
06/18/19
14:50
Hot Stocks
E.W. Scripps reports consent decree to settle DOJ civil case »

In a regulatory filing,…

SSP

E.W. Scripps

$15.02

0.01 (0.07%)

CBS

CBS

$49.38

0.22 (0.45%)

FOXA

Fox Corp.

$36.59

0.44 (1.22%)

FOX

Fox Corp.

$36.23

0.44 (1.23%)

TGNA

Tegna

$15.09

0.22 (1.48%)

SBGI

Sinclair Broadcast

$53.51

0.01 (0.02%)

NXST

Nexstar

$102.72

2.31 (2.30%)

MDP

Meredith

$53.04

0.88 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 25

    Jun

  • 06

    Aug

  • 08

    Aug

  • 13

    Nov

WFC

Wells Fargo

$46.25

0.99 (2.19%)

, GS

Goldman Sachs

$195.72

4.98 (2.61%)

14:50
06/18/19
06/18
14:50
06/18/19
14:50
Periodicals
Wells Fargo dismissed from VRDO lawsuit, Reuters reports »

Wells Fargo & Co…

WFC

Wells Fargo

$46.25

0.99 (2.19%)

GS

Goldman Sachs

$195.72

4.98 (2.61%)

JPM

JPMorgan

$111.21

2.01 (1.84%)

BAC

Bank of America

$28.72

0.79 (2.83%)

BCS

Barclays

$7.59

0.09 (1.20%)

C

Citi

$68.12

1.59 (2.39%)

RY

Royal Bank of Canada

$78.69

1.45 (1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 09

    Jul

  • 13

    Jul

  • 13

    Jul

  • 15

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 17

    Jul

  • 06

    Aug

  • 13

    Aug

  • 21

    Aug

  • 12

    Oct

ADBE

Adobe

$278.26

2.67 (0.97%)

14:49
06/18/19
06/18
14:49
06/18/19
14:49
Options
Adobe options imply 5.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

RARX

RA Pharmaceuticals

$22.36

-0.38 (-1.67%)

14:48
06/18/19
06/18
14:48
06/18/19
14:48
Recommendations
RA Pharmaceuticals analyst commentary  »

RA Pharmaceuticals price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

FITB

Fifth Third

$27.53

0.58 (2.15%)

14:46
06/18/19
06/18
14:46
06/18/19
14:46
Hot Stocks
Fifth Third boosts quarterly dividend 9% to 24c »

Fifth Third Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

MAS

Masco

$38.12

0.22 (0.58%)

14:42
06/18/19
06/18
14:42
06/18/19
14:42
Recommendations
Masco analyst commentary  »

Masco sale of cyclical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKX

Skechers

$31.69

0.82 (2.66%)

14:25
06/18/19
06/18
14:25
06/18/19
14:25
Options
Skechers call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLT

Poly

$44.03

0.98 (2.28%)

14:25
06/18/19
06/18
14:25
06/18/19
14:25
Conference/Events
Poly participates in an investor webinar with Northland Capital Markets »

Northland Capital Markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 18

    Jun

  • 28

    Jun

  • 13

    Nov

14:25
06/18/19
06/18
14:25
06/18/19
14:25
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a hearing »

The Subcommittee on…

GIII

G-III Apparel

$26.38

0.71 (2.77%)

14:18
06/18/19
06/18
14:18
06/18/19
14:18
Hot Stocks
G-III Apparel up 6% after CEO buys over $1M worth of shares »

G-III Apparel Group CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 09

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
06/18/19
06/18
14:17
06/18/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
06/18/19
06/18
14:16
06/18/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPW

DPW Holdings

$0.14

-0.003 (-2.13%)

14:15
06/18/19
06/18
14:15
06/18/19
14:15
Hot Stocks
Breaking Hot Stocks news story on DPW Holdings  »

Digital Power trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jul

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$292.33

2.87 (0.99%)

14:06
06/18/19
06/18
14:06
06/18/19
14:06
Periodicals
USTR says China tariffs only recourse given dialogue has failed, Reuters says »

U.S. Trade Representative…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$292.33

2.87 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$27.10

0.67 (2.54%)

14:05
06/18/19
06/18
14:05
06/18/19
14:05
Options
Arrowhead call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

DPW

DPW Holdings

$0.14

-0.003 (-2.13%)

14:01
06/18/19
06/18
14:01
06/18/19
14:01
Hot Stocks
DPW Holdings announces deal with senior lender to refinance outstanding debt »

DPW Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jul

CMCSA

Comcast

$43.10

0.54 (1.27%)

, CHTR

Charter

$396.65

2.64 (0.67%)

13:58
06/18/19
06/18
13:58
06/18/19
13:58
Hot Stocks
Comcast says Charter, Cox join 'On Addressability' initiative »

Comcast Advertising, the…

CMCSA

Comcast

$43.10

0.54 (1.27%)

CHTR

Charter

$396.65

2.64 (0.67%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

CVS

CVS Health

$54.84

0.32 (0.59%)

13:55
06/18/19
06/18
13:55
06/18/19
13:55
Conference/Events
CVS Health participates in a conference call with JPMorgan »

Healthcare Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 18

    Jun

GOOG

Alphabet

$1,107.00

14.75 (1.35%)

, GOOGL

Alphabet Class A

$1,110.00

17.29 (1.58%)

13:54
06/18/19
06/18
13:54
06/18/19
13:54
Periodicals
Google tells Bloomberg issues with calendar resolved »

Google said in a…

GOOG

Alphabet

$1,107.00

14.75 (1.35%)

GOOGL

Alphabet Class A

$1,110.00

17.29 (1.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 09

    Jul

  • 10

    Jul

  • 27

    Oct

NVO

Novo Nordisk

$52.19

1.19 (2.33%)

13:52
06/18/19
06/18
13:52
06/18/19
13:52
Hot Stocks
Novo Nordisk sNDA for expanded Victoza age range approved by FDA »

A letter posted on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

DPW

DPW Holdings

$0.14

-0.002 (-1.42%)

13:46
06/18/19
06/18
13:46
06/18/19
13:46
Hot Stocks
Breaking Hot Stocks news story on DPW Holdings  »

Digital Power trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.